While the 14-day course of primaquine (0.25–0.5 mg/kg per day for 14 days) treatment required for the radical cure of P. vivax malaria is considered to be unsafe for G6PD-deficient (G6PDd) individuals, the WHO considers a single low dose (0.25 mg/kg) of primaquine to be safe for individuals with G6PD-deficiency, as implied by their recommendation to use primaquine as a P. falciparum gametocytocide [6]. This evidence concerns the gene G6PD and hyperinsulinemic hypoglycemia, familial, 4.